Skyrizi cleared psoriasis in far more people than Humira (72% vs 47%)
“Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.” Reich K et al. The Lancet. August 2019
Reich K et al. · The Lancet · August 2019